However, the IC50 of PMIBcr/Abl‐R6 is almost half that of Bcr/ABl‐R6, proving that inhibiting Bcr/Abl oligomerization shows efficacy in treating Ph+ leukemia cells, our PROTAC drug functions more effectively than the original antagonist. This evidence concerns the gene BCR and leukemia.